“Clinical and Economic Rationale for the Early Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes”. 2020. Farmeconomia. Health Economics and Therapeutic Pathways 21 (1S). https://doi.org/10.7175/fe.v21i1S.1490.